Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about STOK, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Meperidine | Pain Relief in Labour | Phase 4 · NCT02179294 | Completed |
| Remifentanil | Pain Relief in Labour | Phase 4 · NCT02179294 | Completed |
| Zorevunersen | Dravet Syndrome | Phase 3 · NCT06872125 | Active not recruiting |
| STK-001 - Multiple Ascending Doses | Dravet Syndrome | Phase 1/2 · NCT04442295 | Completed |
| STK-001 - Single Ascending Doses | Dravet Syndrome | Phase 1/2 · NCT04442295 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
STOK holds $358.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $59.6M/quarter from operations, an estimated runway of 18 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when STOK files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RTW Investments, LP | Institution (13G, 5%+) | 5,940,866 | 9.08% | 2026-03-31 |
| FMR LLC | Institution (13G, 5%+) | 4,820,462 | 7.37% | 2026-09-30 |
| Redmile Group, LLC | Institution (13G, 5%+) | 4,164,120 | 6.37% | 2026-03-31 |
| Lynx1 Capital Management LP | 5%+ holder (13G) | 4,038,404 | 6.17% | 2026-06-30 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 3,608,968 | 5.52% | 2026-09-23 |
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 3,336,697 | 5.10% | 2025-12-31 |
| Wellington Management Group LLP | Institution (13G, 5%+) | 3,095,700 | 4.73% | 2026-03-31 |
| Adrian R. Krainer Director · +17,786 options |
Insider | 283,302 | 0.43% | 2026-03-10 |
| Edward M. MD Kaye Director · +105,786 options |
Insider | 124,557 | 0.19% | 2026-08-14 |
| Arthur Tzianabos Director · +136,482 options |
Insider | 31,339 | 0.05% | 2026-03-10 |
| Arthur A Levin Director · +17,786 options |
Insider | 22,216 | 0.03% | 2026-03-13 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC · +55,475 options |
Insider | 20,598 | 0.03% | 2026-10-02 |
Share count 65,406,268 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for STOK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →